[HTML][HTML] Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
JJ Sabatino Jr, K Mittl, WM Rowles, K McPolin… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-CoV-2
infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target …
infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target …
[HTML][HTML] Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
…, A Bystrup, KE Byg, IS Johansen, K Mittl… - Multiple sclerosis and …, 2021 - Elsevier
Background The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20
monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of …
monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of …
[HTML][HTML] Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1 …
Background Adequate response to the SARS-CoV-2 vaccine represents an important
treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID-19 …
treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID-19 …
[HTML][HTML] Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
JJ Sabatino Jr, K Mittl, W Rowles, K Mcpolin, JV Rajan… - medRxiv, 2021 - ncbi.nlm.nih.gov
Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and
control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse …
control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse …
SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron
…, C Marquez, JJ Sabatino Jr, K Mittl… - The Journal of …, 2022 - academic.oup.com
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with phenotypes impacting transmission and antibody sensitivity necessitates …
variants with phenotypes impacting transmission and antibody sensitivity necessitates …
[HTML][HTML] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple …
…, AH Witt, KE Byg, IS Johansen, K Mittl… - Multiple Sclerosis and …, 2022 - Elsevier
Objective To examine humoral and cellular response in multiple sclerosis patients on anti-CD20
therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A prospective …
therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A prospective …
Monoclonal antibody-based sandwich ELISA for the detection of mammalian meats
X Jiang, Q Rao, K Mittl, YHP Hsieh - Food control, 2020 - Elsevier
In order to (1) reduce the risk of intentional or unintentional contamination of foods, (2) better
comply with food regulations, and (3) decrease economic loss to the food industry caused …
comply with food regulations, and (3) decrease economic loss to the food industry caused …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
…, MVM Hvidt, KE Byg, IS Johansen, K Mittl… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-…
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the anti-…
Exposures to different SARS-CoV-2 spike variants elicit neutralizing antibody responses with differential specificity towards established and emerging strains
…, KC Zorn, L Rubio, S Bravo, JJ Sabatino, K Mittl… - 2021 - pesquisa.bvsalud.org
… Matthew T Laurie; Jamin Liu; Sara Sunshine; James Peng; Douglas Black; Anthea M
Mitchell; Sabrina A Mann; Genay Pilarowski; Kelsey C Zorn; Luis Rubio; Sara Bravo; …
Mitchell; Sabrina A Mann; Genay Pilarowski; Kelsey C Zorn; Luis Rubio; Sara Bravo; …
Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
…, K Østergaard, AH Witt, KE Byg, IS Johansen, K Mittl… - medRxiv, 2022 - medrxiv.org
Objective To examine humoral and cellular response in multiple sclerosis patients on anti-CD20
therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A prospective …
therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. Methods A prospective …
